Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

Life sciences hubs beyond Boston and the Bay Area are giving startups new opportunities to grow and scale their businesses, ...

Regulatory submissions are entering a period of meaningful structural change. eCTD 4.0 is gaining traction at both the FDA and EMA, offering practical improvements over its predecessor: more flexible ...

A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work ...

For many families living with rare pediatric diseases, hope often arrives quietly — after years of uncertainty, missed diagnoses, and being told that treatment may never come in time. For Lindsey ...

Each January, the J.P. Morgan Healthcare Conference helps to set the biopharmaceutical industry agenda for the coming year, and more suits can be seen on the streets of San Francisco than during any ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access. The question is no longer if, but how. Pharmaceutical companies ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

As biotech companies face decreasing productivity, they need ways to do more with less, and fast. A fresh approach to achieve this is by rethinking how innovation is structured: collaborate early and ...